Business
Bruker is Ushering in the Age of Spatial Single-Cell Metabolomics
Novel unbiased, in situ Spatial Single-Cell Metabolomics (SSCM) enables high-throughput metabolic tissue characterization with single-cell resolution New 5
About this update from Bruker Corporation
[{"type":"text","content":"\n\nNovel unbiased, in situ Spatial Single-Cell Metabolomics (SSCM) enables high-throughput metabolic tissue characterization with single-cell resolution\n\n\nNew 5 µm microGRID™ technology for timsTOF® fleX MALDI mode provides virtually artifact-free small-molecule images across large field of view \n\n\nNovel 4D-Metabolomics methods use CCS-Predict Pro AI/DL to enrich lipids, metabolite, and glycan libraries with molecular collision cross sections (CCS)\n\n\n VALENCIA, Spain--(BUSINESS WIRE)--\nAt the 18th International Conference of the Metabolomics Society, Bruker Corporation (Nasdaq: BRKR) announced key innovations for spatial multiomics with a focus on unbiased Spatial Single-Cell Metabolomics (SSCM) for probing differential cellular phenotypes based on the metabolic signature of tissues and single cells.\n\nCombining SSCM with the recently announced MALDI HiPLEX-IHC workflow enables in situ single cell immunometabolomics studies that integrate metabolomics-based immune reprogramming with targeted proteomics. This single-cell multiomics workflow is enabled by the new microGRID™ smartbeam™ 3D MALDI source for timsTOF® fleX systems for sub-micron positioning for spatial resolution down to five micrometers (5 µm), virtually eliminating any artifacts in the co-registration of MALDI molecular images with optical microscopy.\n\nSingle-cell technologies have revolutionized the understanding of heterogeneous biological processes underlying cancer, regenerative medicine, aging, and liver diseases. Studying cell-to-cell tissue variation enhances translational research, for example, in the development of better cancer research methods for the development of therapeutics targeting rare tumor cells.\n\nProfessor Theodore Alexandrov, Head of the Metabolomics Core Facility and Molecular Medicine Partnership Unit at the EMBL in Heidelberg, Germany, will lead a new project called SpaceM in the BioStudio Faculty of the BioInnovation Institute in Copenhagen, Denmark, focusing on single-cell metabolomics for drug discovery and precision medicine.\n\nDr. Alexandrov commented: “We are in the process of developing the SpaceM technology for spatial single-cell metabolomics, developed at EMBL Heidelberg, into a platform for rapid drug discovery. As part of the BioStudio program at the BioInnovation Institute in Copenhagen, we will use a timsTOF fl...